Crystalline compound
Patent Information
- Application Number
- JP2023036730
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2015-06-17
- Filing Date
- 2023-03-09
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2036-06-17
AI Technical Summary
Active pharmaceutical ingredients like (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane exist in various physical forms with differing processability, stability, solubility, and bioavailability, making it challenging to predict and utilize their advantageous polymorphs in pharmaceutical compositions.
The discovery and characterization of specific polymorphic forms, such as crystalline Form A and B of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride, which have distinct stability and solubility properties, enabling their use in galenic preparations.
These crystalline forms enhance the stability and solubility of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, improving the effectiveness of pharmaceutical compositions by addressing variability in physical forms.
Smart Images

Figure 0007583851000041 
Figure 0007583851000042 
Figure 0007583851000043
Abstract
Citation Information
Patent Citations
Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20140206740A1
